Identification of Mycobacteria Species by HPLC and Species Distribution during Five Years at Ulsan University Hospital / 대한진단검사의학회지

BACKGROUND: Infections caused by mycobacteria have been significantly increasing. Due to the difficulty of making a decision about the pathogenicity of mycobacteria, species-level identification is very important for patients' diagnosis and treatment. The purpose of this study was to identify mycobacteria species using a high performance liquid chromatography (HPLC) method and to provide an initial database for the distribution of mycobacteria in Korea. METHODS: Acid fast bacteria isolated from 3,107 clinical specimens were identified by mycolic acid analysis using HPLC. The HPLC patterns were compared with those of standard mycobacteria species. RESULTS: The HPLC patterns were divided into single, double, and triple cluster groups, each group comprising 9, 20, and 4 species, respectively. Mycobacteria and non-tuberculous mycobacteria (NTM) were identifies by HPLC at the rates of 99.5% and 95.6%, respectively. NTM was isolated in 12.4% of the mycobacteria positive specimens. This study also found that there were 20 different NTM species with the distribution of each species ranging from 0.3% to 15.9% of the total NTM. While the rate of NTM has been increasing in Korea, M. avium-intracellulare, M. fortuitum, and M. chelonae are relatively decreasing, and M. kansasii and M. gordonae are relatively increasing. CONCLUSIONS: HPLC method was highly discriminative for the identification of NTM in clinical specimens.

Possibilidades do G 30 320 no tratamento da hanseniase e da reação leprotica / Possibilities of G 30 320 me the treatment of leprosy and reaction leprosy

Os AA selecionaram doentes de lepra internados no Hospital Colonia Curupaiti e Hopsital Frei Antonio do Estado da Guanabara, Brasil, para experimentação da atividade antilepra do G 30 320. Todos oos pacinetes são da forma lepromatosa graus L1, L2,L3 e dimorfos, classificados nos seguinte Grupos:I - Doentes novos, virgens de tratamentoII - Doentes sulfono-resistentes com lepra progressiva avançadaIII - Doentes sujeitos a reação tipo ENL, talidomido dependentes. Desencadeia-se a reação sempre que se instituti tratamento sulfonico sem a respectiva e continua cobertura com talidomidaIV - Doentes talidomida insensiveis sujeitos a reação de ENI incontrolavel pelos metodos tradicionais inclusive talidomidaA experiencia tem por objetivo a verificação da utilidade do novo produito G 30 320 no controle do desenvvolvimento da Hanseniase e da reação leprotica. O esquema basico de administração tem sido 2 capisulas por dia durante 7 dias reduzindo-se então para l capsula diaria. Cada capsula contem l00 mg. de um derivado anilino aposafraninado G 30 320...